RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today, at the EUROGIN 2024 HPV Congress, announced plans to initiate clinical development of a new investigational multi-valent HPV vaccine designed to provide broader protection against multiple HPV types. Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recomb ...

Merck & Co., Inc. (NYSE:MRK) Barclays 26th Annual Global Healthcare Conference March 12, 2024 3:05 PM ET Company Participants Jannie Oosthuizen - President, Human Health U.S. Peter Dannenbaum - Vice President, Investor Relations Conference Call Participants Carter Gould - Barclays Carter Gould Good afternoon and welcome to Day One of the Barclays Global Healthcare Conference. My name is Carter Gould, covering U.S. Biopharma. I'm pleased to welcome Merck to the stage. Merck is one of our top picks to start t ...

Merck & Co., Inc. (NYSE:MRK) Leerink Partners 2024 Global Biopharma Conference Call March 11, 2024 12:40 PM ET Company Participants Marjorie Green - SVP and Head of Oncology Peter Dannenbaum - VP, IR Conference Call Participants Daina Graybosch - Leerink Partners Daina Graybosch Hi, everyone. Thank you for coming to the session. My name is Daina Graybosch. I and my team cover immuno-oncology and beyond here at Leerink Partners. And I'm really excited to have a great oncology conversation with Merck. We have ...

Merck (MRK) ended the recent trading session at $123.99, demonstrating a +0.19% swing from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 1.03%. At the same time, the Dow added 0.34%, and the tech-heavy Nasdaq gained 1.51%.The pharmaceutical company's stock has dropped by 2.92% in the past month, falling short of the Medical sector's gain of 2.1% and the S&P 500's gain of 3.21%.The upcoming earnings release of Merck will be of great interest to investors. In ...

Company and Industry Overview * **Company**: Merck & Co., Inc. (NYSE:MRK) * **Industry**: Healthcare, Pharmaceuticals, Biotechnology Key Points GARDASIL * **Revenue Target**: Merck aims to achieve $11 billion in GARDASIL revenue by 2030, driven by international markets. * **International Expansion**: Merck focuses on increasing vaccine coverage rates, expanding coverage in NIPs, and targeting the private market and low middle-income segments. * **Manufacturing Capacity**: Merck has invested in manufacturing capacity to meet growing demand for GARDASIL, particularly in low middle-income markets. KEYTRUDA * **Growth Outlook**: KEYTRUDA is expected to see growth in 2024, driven by expansion into new tumor types and earlier treatment settings. * **Early-Stage Settings**: Early-stage KEYTRUDA is expected to be the primary driver of growth in 2024, with significant potential in triple-negative breast cancer and other tumor types. * **Subcutaneous Formulation**: Merck is exploring the subcutaneous formulation of KEYTRUDA for O-U.S. markets, aiming to improve patient convenience and access. Sotatercept * **PAH Approval**: Merck is confident in the approval of sotatercept for PAH in the EU and Japan, with a potential launch in the second half of 2024. * **Market Opportunity**: Sotatercept has the potential to become a significant revenue driver for Merck, with a target cardiovascular business of $15 billion by the mid-2030s. Vaccines * **Prevnar**: Merck is focused on expanding the Prevnar franchise, including the launch of VAXNEUVANCE for the pediatric segment and V116 for the adult segment. * **Dengue**: Merck is developing a dengue vaccine with potential for significant impact in the Southern Hemisphere and other regions. * **VAXELIS**: Merck is making steady progress with VAXELIS, a hexavalent vaccine covering multiple diseases. HIV * **Islatravir-Doravirine Combination**: Merck is developing an islatravir-doravirine combination for HIV, aiming to differentiate from existing treatments and address unmet needs. China * **Market Growth**: Merck has seen significant growth in China, driven by the launch of GARDASIL and other innovative products. * **Government Support**: The Chinese government's focus on improving healthcare standards and access has been beneficial for Merck. * **Partnerships**: Merck has formed partnerships with local companies to leverage the growing scientific ecosystem in China. Future Outlook * **Competitive Advantage**: Merck's competitive advantage lies in its pipeline of innovative products and its focus on patient care. * **Long-Term Growth**: Merck is focused on long-term growth, with a focus on expanding its pipeline and addressing unmet medical needs.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories, is scheduled to participate in a fireside chat at the Leerink Partners Global Biopharma Conference 2024 on Monday, March 11, 2024, at 12:40 p.m. ET. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of t ...

Merck (MRK) ended the recent trading session at $126.96, demonstrating a -0.15% swing from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 0.8%. At the same time, the Dow added 0.23%, and the tech-heavy Nasdaq gained 1.14%.Shares of the pharmaceutical company have appreciated by 0.61% over the course of the past month, underperforming the Medical sector's gain of 3.58% and the S&P 500's gain of 5.2%.Analysts and investors alike will be keeping a close eye on t ...

A pharmacist serves a customer at a pharmacy. Hispanolistic/E+ via Getty Images Anybody who has followed the stock market for some time knows that it can be quite volatile. All it takes is a poor or great earnings report, or underwhelming or better-than-expected guidance, and a stock can slump or jump by 5%, 10%, or more. One stock that has climbed higher since I last recommended it as a buy in December is Merck (NYSE:MRK). As the S&P 500 (SP500) has gained 6%, the pharmaceutical juggernaut has soared 19% ...

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this pharmaceutical company have returned +6.1% over the past month versus the Zacks S&P 500 composite's +4% change. The Zacks Large Cap Pharmaceuticals industry, to which Merck belongs, has gained 7.9% over this period. Now the key question is: Where could the stock be headed in the near term?Wh ...

Despite markets continuing at record highs, Charles Schwab (NYSE:SCHW) Investment Management still identifies investment opportunities within long-term stocks. According to its recent filings, the respected investment house perceives potential upside in interesting companies, increasing holdings.The top 5 Charles Schwab stocks include Microsoft (NASDAQ:MSFT), Apple (NASDAQ:AAPL), Amazon (NASDAQ:AMZN), Nvidia (NASDAQ:NVDA) and Broadcom (NASDAQ:AVGO) stakes. These are the long-term stocks to which Charles Sch ...